This product is a human monoclonal IgG kappa antibody targeting human hepatitis B surface antigen. Antibody C9G9 can effectively block the HBV replication in vitro, and therefore has a good ability to neutralize the hepatitis B virus, as prevention of HBV infection drugs.
Figure 1 HBV-neutralizing activity of the bispecific antibodies.
(D) The binding of C1G1 and 2B5F5 to HBsAg was markedly reduced when HBsAg was preincubated with C4D2-BsAb but not with C4G4 plus D2H2. C4G4 plus D2H2, or C4D2-BsAb was first incubated with biotinHBsAg. The mixtures were then transferred to the plates coated with anti-HBsAg antibodies A3E3, A6E6, B7F7, C1G1, C9G9, D10H10, 2B5F5, 2C7G7, 2D4H4 and 2D5H5. After 2 h incubation, the plates were washed and biotin-HBsAg bound were detected with HRP-strepavidin conjugated. Results were shown as mean ± SD of three independent experiments.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For research use only. Not intended for any clinical use.